NVS

Novartis
D

NVS

Arincen80/100B

If you had invested in Novartis ago, it would be worth $3,435 today, against $3,697 in SPY and $5,557 in QQQ.

ArincenArincen ScoreBeta

80/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Novartis key facts

Style
Dividend stock · 6.7/10Growth 2.8 · Value 4.6 · Dividend 6.7
Day range
150.230 – 152.710
52-week range
126.500 – 170.460
Market capitalization
284.22B USD
P/E
28.66
PEG ratio
2.27
EPS
5.25
Div Yield
3.15%
EPS growth forecast (FY2026)
-0.6%
Volume
102,798
Beta
0.41
ESG score
73.8/100Environment 73 · Social 75 · Governance 74
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Vasant Narasimhan
Employees
75K
IPO date
7 Nov 1996

Novartis earnings

Next earnings · Q4 FY2026
EPS estimate
2.23 USD
Revenue estimate
14.65B USD
Last quarter · Q3 FY2026
EPS2.46Beat +9.3%Revenue14.52BMissed -0.1%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q4 FY20262.23——+9.85%14.65B——+9.83%
Q3 FY20262.252.46+9.33%+9.33%14.53B14.52B-0.07%+1.14%
Q2 FY20262.172.41+11.06%-0.41%14.07B14.41B+2.43%+0.90%
Q1 FY20262.111.99-5.69%-12.72%13.44B13.11B-2.42%-3.72%
Q4 FY20251.992.03+2.01%+2.53%13.70B13.34B-2.69%-1.64%
Q3 FY20252.262.25-0.44%+9.22%13.64B14.36B+5.25%+9.00%
Q2 FY20252.382.42+1.68%+22.84%13.94B14.28B+2.47%+14.13%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

Novartis analyst forecast

12-month price target
149.50 USD
-0.66%

Analysts' 1-year price targets range from 136.00 to 163.00, with an average of 149.50.

Past year
1-year forecast
Strong sellStrong buy
Hold
5 ratings
Buy
2
Hold
2
Sell
1

12-month price target

Highest target163.00
Average target149.50
Lowest target136.00
Current price150.49

Novartis valuation

Price to earnings ratio (TTM)
28.66
Forward P/E (FY2026)
16.87
Price to sales (TTM)
5.05
Price to book
7.63
EV / EBITDA (TTM)
14.85

Capital structure

Market capitalization
284.22B USD
+
Total debt
48.31B USD
−
Cash and short-term investments
8.98B USD
=
Enterprise value
323.55B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)13.83————
FY2027 (est.)15.1813.83———
FY2026 (est.)16.8715.18———
Now (TTM)28.6615.355.057.6314.85
FY202519.1215.454.725.8012.76
FY202416.4410.903.804.4610.44
FY202314.1213.404.494.4912.20
FY202226.9112.884.313.1614.14
FY20217.7314.524.222.746.61

Novartis against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Merck & Co., Amgen, Gilead Sciences, AbbVie, Pfizer, and Johnson & Johnson, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Above its median28.7
    6.931.4
  • Gross marginHighest in 5 years75.8%
    73.3%75.8%
    Against its peers: 2 of 7Peers' median 71.4%
  • Operating marginHighest in 5 years31.1%
    18.3%31.1%
    Against its peers: 3 of 7Peers' median 27.5%
  • Net marginAt its median24.7%
    16.0%54.6%
    Against its peers: 4 of 7Peers' median 24.6%
  • Return on equityAt its median30.3%
    11.7%35.5%
    Against its peers: 5 of 6Peers' median 34.7%
  • Free cash flow marginHighest in 5 years31.0%
    25.1%31.0%
    Against its peers: 2 of 7Peers' median 21.5%
  • Revenue growthAbove its median9.6%
    -11.9%10.8%
    Against its peers: 2 of 7Peers' median 4.2%
  • EPS growthAt its median21.8%
    -70.2%202.0%
    Against its peers: 4 of 7Peers' median 48.1%
  • Debt to EBITDAAbove its median1.55×
    1.00×1.90×
    Against its peers: 2 of 7Peers' median 2.53×
  • Current ratioBelow its median1.12
    1.041.51
    Against its peers: 5 of 7Peers' median 1.15

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Novartis growth and profitability

Revenue (TTM)
56.31B USD
Net income (TTM)
10.03B USD
Gross margin
74.62%
Operating margin
25.46%
Net margin
17.82%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202556.67B+9.57%13.98B+17.11%75.83%31.13%24.67%22.82B+10.17%
FY202451.72B+10.85%11.94B-19.59%75.20%28.12%23.09%20.72B+13.48%
FY202346.66B+7.36%14.85B+113.52%73.27%20.94%31.83%18.26B+24.34%
FY202243.46B-1.17%6.96B-71.05%73.35%18.28%16.00%14.68B-52.51%
FY202143.97B-11.87%24.02B+197.58%73.31%22.87%54.63%30.91B+79.62%

How Novartis makes its money

Revenue56.67B 100.0%
Cost of revenue13.70B 24.2%
Gross profit42.98B 75.8%
Research and development11.20B 19.8%
Selling and administration13.25B 23.4%
Other operating expenses883.00M 1.6%
Operating income17.64B 31.1%
Tax2.39B 4.2%
Other expense1.28B 2.2%
Net income13.98B 24.7%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Novartis dividends

Annual dividend
4.74 USD
Dividend yield (indicated)
3.15%
Payout ratio
90.29%
Years of dividend growth
2
Frequency
Annual
Last payment
4.74 USD
Last ex-dividend date
11 Mar 2026
Last payment date
16 Mar 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share3.993.203.503.333.203.092.572.672.462.47

Novartis financial health

Cash and short-term investments
8.98B USD
Total debt
48.31B USD
Net cash
-39.34B USD
Free cash flow (TTM)
15.82B USD
Current ratio
0.88
Debt to equity
1.30
Piotroski score
7 / 9
Altman Z-score
3.45

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY202511.59B35.38B17.60B
FY202413.35B31.26B13.81B
FY202313.96B26.35B11.71B
FY202218.62B27.91B12.00B
FY202128.11B31.03B12.52B

Novartis ownership

Institutions
7.02%
Institutional holders
1,610 (-70)
Free float
96.92%

Who owns the shares

Institutions 7.0% Others 93.0%
As of 30 Sept 2026

Shares free to trade

Free float 1.83B shares ·96.9% Closely held 58.26M shares ·3.1%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY20251.94B1.96B-3.93%
FY20242.02B2.04B-2.72%
FY20232.08B2.09B-4.78%
FY20222.18B2.20B-2.79%
FY20212.24B2.26B-1.57%

Source: Financial Modeling Prep

Related Instruments

Title: Novartis AG

Sector: Healthcare
Industry: Drug Manufacturers - General
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Common questions about Novartis stock